- Home
- Services
- asia middle east
- bioreactor
Show results for
Refine by
Locations
- Asia & Middle East
- Afghanistan
- Armenia
- Azerbaijan
- Bahrain
- Bangladesh
- Bhutan
- Brunei Darussalam
- Cambodia
- China
- East Timor
- Georgia
- Guam
- India
- Indonesia
- Iran
- Iraq
- Israel
- Japan
- Jordan
- Kazakhstan
- Kuwait
- Kyrgyzstan
- Laos
- Lebanon
- Malaysia
- Maldives
- Mongolia
- Myanmar
- Nepal
- North Korea
- Oman
- Pakistan
- Palestinian Territories
- Philippines
- Qatar
- Russia
- Saudi Arabia
- Singapore
- South Korea
- Sri Lanka
- Syria
- Taiwan
- Tajikistan
- Thailand
- Turkmenistan
- United Arab Emirates
- Uzbekistan
- Vietnam
- Yemen
Bioreactor Services In Asia Middle East
4 services found
Manufactured by:Accellta based inHaifa, ISRAEL
Process development services for culturing stem cells and or their derivatives in feeder-free, xeno-free, serum-free 3D non-adherent conditions in spinners and bioreactors. Process development services for differentiation of stem cells to the desired cell type in feeder-free, xeno-free, serum-free 3D non-adherent conditions in spinners or bioreactors. Protocols ...
by:ABEC, INC. based inBethlehem, PENNSYLVANIA (USA)
The CSR product line leads the industry with bioreactor volumes up to 6,000L Vw, fermenter volumes up to 1,000L Vw, and liquid mixing systems up to 7,000L Vw, delivering significantly more capacity per unit area of floor space; a key metric in high-value multi-product biopharmaceutical facilities. ...
Manufactured by:Minaris Regenerative Medicine, LLC based inAllendale, NEW JERSEY (USA)
Minaris Regenerative Medicine’s manufacturing development services help you to design efficient and robust manufacturing processes for your cell and gene therapy. Keeping the ultimate goal of commercial supply in mind, we help you think beyond your current manufacturing needs to create approaches that improve the commercial viability of your products. We keep in mind four key elements of ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for major markets including the United States, Europe, Japan and ...